Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15063 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Ronnie Aronson und 8 weiteren Autor:innen. Beteiligte Einrichtung: LMC Diabetes and Endocrinology, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Aim
This study compared the pharmacokinetics, glucodynamics and tolerability following single subcutaneous doses of ultra rapid lispro (URLi) versus Humalog in children (6‐11 years), adolescents (12‐17 years) and adults (18‐64 years) with type 1 diabetes mellitus (T1D). Materials and Methods The study was a randomized, two‐period, subject‐ and investigator‐blind, crossover design in participants with T1D. Participants received a 0.2 U/kg bolus dose immediately before a liquid mixed meal tolerance test. Insulin lispro and glucose concentrations were measured.
Results
The study included 13 children, 14 adolescents and 15 adults. Consistently across the age groups, onset of appearance was 4‐5 min faster, the early 50% t max was reduced by 7‐13 min, and exposure in the first 15 min was increased by 3.5‐6.5‐fold following URLi compared with Humalog (all p < .01). Exposure after 3 h was decreased by 37‐58% ( p = .02) and the duration was reduced by 56 min ( p = .006) in children and 36 min ( p = .022) in adolescents with URLi compared with Humalog. The maximum and overall exposure were similar between treatments. Postprandial glucose at 1 h was reduced by 42 mg/dl in children ( p = .008), 19 mg/dl ( p = .195) in adolescents and 34 mg/dl ( p = .018) in adults following URLi versus Humalog. The glucose excursion during a 5‐h test meal period was reduced by 16% in children and 9% in adolescents compared with Humalog. URLi was well tolerated in all age groups.
Conclusions
URLi showed an accelerated insulin lispro absorption and greater postprandial glucose reduction compared with Humalog in children, adolescents and adults with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LMC Diabetes and Endocrinology, Toronto, Ontario, Canada.
- Diabetes Center for Children and Adolescents, Children's Hospital AUF DER BULT, Hannover, Germany.
- Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
ORCID-Profile: Ronnie Aronson, Torben Biester, Jennifer Leohr, Robyn Pollom, Helle Linnebjerg, Thomas Danne
Förderung
- Eli Lilly and Company
Zitieren
APA
Aronson, R., Biester, T., Leohr, J., Pollom, R., Linnebjerg, H., LaBell, E. S., Zhang, Q., Coutant, D. E., & Danne, T. (2023). Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15063
Vancouver
Aronson R, Biester T, Leohr J, Pollom R, Linnebjerg H, LaBell ES, et al. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15063
BibTeX
@article{Aronson2023,
author = {Aronson, Ronnie and Biester, Torben and Leohr, Jennifer and Pollom, Robyn and Linnebjerg, Helle and LaBell, Elizabeth Smith and Zhang, Qianyi and Coutant, David E and Danne, Thomas},
title = {Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15063}
}
EUVIMED